Novo Nordisk
E455777
Novo Nordisk is a global healthcare company based in Denmark, best known as a leading producer of insulin and other diabetes care treatments.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Novo Nordisk global corporate structure | 1 |
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
Biotechnology company
ⓘ
Pharmaceutical company ⓘ Public company ⓘ |
| country | Denmark ⓘ |
| focusesOn |
Chronic disease management
ⓘ
Metabolic disorders ⓘ |
| formedByMergerOf |
Nordisk Gentofte
NERFINISHED
ⓘ
Novo Industri NERFINISHED ⓘ |
| foundedBy |
August Krogh
NERFINISHED
ⓘ
Hans Christian Hagedorn NERFINISHED ⓘ Marie Krogh NERFINISHED ⓘ |
| hasDivision |
Diabetes and Obesity Care
NERFINISHED
ⓘ
Rare Disease ⓘ |
| hasParentOrganization | Novo Holdings NERFINISHED ⓘ |
| hasSubsidiary | Novo Nordisk Inc. NERFINISHED ⓘ |
| headquartersLocation | Bagsværd, Denmark NERFINISHED ⓘ |
| inception | 1923 ⓘ |
| industry |
Biotechnology industry
ⓘ
Healthcare ⓘ Pharmaceutical industry ⓘ |
| legalForm | Aktieselskab ⓘ |
| listedOn | New York Stock Exchange ⓘ |
| majorProduct |
Levemir
NERFINISHED
ⓘ
NovoRapid ⓘ Ozempic NERFINISHED ⓘ Rybelsus NERFINISHED ⓘ Saxenda NERFINISHED ⓘ Tresiba NERFINISHED ⓘ Victoza NERFINISHED ⓘ Wegovy NERFINISHED ⓘ |
| memberOf |
EFPIA
NERFINISHED
ⓘ
International Diabetes Federation corporate partners ⓘ |
| numberOfEmployees | over 50,000 ⓘ |
| operatesIn |
Africa
ⓘ
Asia ⓘ Europe ⓘ Latin America ⓘ North America ⓘ |
| researchFocus |
GLP-1 receptor agonists
NERFINISHED
ⓘ
Insulin analogues ⓘ Obesity pharmacotherapy ⓘ |
| specializesIn |
Diabetes care
ⓘ
Growth hormone therapy ⓘ Haemophilia treatment ⓘ Insulin production ⓘ Obesity care ⓘ |
| stockExchange | Nasdaq Copenhagen NERFINISHED ⓘ |
| tickerSymbol |
NOVO-B
NERFINISHED
ⓘ
NVO NERFINISHED ⓘ |
| website | https://www.novonordisk.com ⓘ |
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Novo Nordisk global corporate structure